Chardan analysts named the firm’s top biotech picks for 2025: MeiraGTx (MGTX), Mind Medicine (MNMD), Prime Medicine (PRME), and Avidity Biosciences (RNA). For Avidity, Chardan does not believe the current stock price imparts any value for the company’s early stage pipeline candidates targeting cardiomyopathies. For Prime, it anticipates a high likelihood of a favorable proof of concept readout in chronic granulomatous disease this year. For MeiraGTx, the firm believes the company’s Parkinson’s disease AAV-GAD gene therapy is well positioned for pivotal studies. For Mind Medicine, Chardan says the company’s lead program MM120 has been clinically de-risked, as the company has demonstrated “robust” proof of concept in the Phase 2 GAD study. .
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: